5

15

CLAIMS

What is claimed is:

- 1. A method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2, comprising contacting said first cell with an effective amount of a humanized immunoglobulin having binding specificity-for B7-2, said immunoglobulin comprising an antigen binding region of nonhuman origin and at least a portion of an immunoglobulin of human origin.
- 2. A method of modulating an immune response of a patient having a transplanted organ, tissue, cell or the like comprising administering an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising an antigen binding region of nonhuman origin, and at least a portion of an immunoglobulin of human origin in a carrier.
- 3. A method for treating a patient having a transplanted organ, tissue or cell, comprising administering a therapeutically effective amount of a humanized antibody having binding specificity for B7-2, said immunoglobulin comprising an antigen binding region of nonhuman origin and at least a portion of an immunoglobulin of human origin.
- 4. The method of claim 2, wherein the carrier is pharmaceutical carrier.
- 5. A method of modulating an immune response of a patient having a transplanted organ, tissue, cell or the like comprising administering an effective amount of a humanized immunoglobulin specific to B7-1 and an effective amount of a humanized immunoglobulin specific to B7-2 in a carrier.

osasen aerzen

Add A8